Molecular pathways and therapeutic strategies in dermatofibrosarcoma protuberans (DFSP)
EXCLI Journal · 14.05.2024 · 23 · 727-762
DOI: 10.17179/excli2024-7164 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 14.05.2024. Verfasst von Harpreet Singh und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, IFTM University, Moradabad, Uttar Pradesh, 244102, India. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Dermatofibrosarcoma Protuberans (DFSP) is a rare soft tissue sarcoma distinguished by its infiltrative growth pattern and recurrence potential. Understanding the molecular characteristics of DFSP is essential for enhancing its diagnosis, prognosis, and treatment strategies. The paper provides an overview of DFSP, highlighting the significance of its molecular understanding. The gene expression profiling has uncovered unique molecular signatures in DFSP, highlighting its heterogeneity and potential therapeutic targets. The Platelet-Derived Growth Factor Receptors (PDGFRs) and Fibroblast Growth Factor Receptors (FGFRs) signaling pathways play essential roles in the progression and development of DFSP. The abnormal activation of these pathways presents opportunities for therapeutic interventions. Several emerging therapies, i.e., immunotherapies, immunomodulatory strategies, and immune checkpoint inhibitors, offer promising alternatives to surgical resection. In DFSP management, combination strategies, including rational combination therapies, aim to exploit the synergistic effects and overcome resistance. The article consisting future perspectives and challenges includes the discovery of prognostic and predictive biomarkers to improve risk stratification and treatment selection. Preclinical models, such as Patient-derived xenografts (PDX) and genetically engineered mouse models, help study the biology of DFSP and evaluate therapeutic interventions. The manuscript also covers small-molecule inhibitors, clinical trials, immune checkpoint inhibitors for DFSP treatment, combination therapies, rational therapies, and resistance mechanisms, which are unique and not broadly covered in recent pieces of literature.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, IFTM University, Moradabad, Uttar Pradesh, 244102, India.
- Department of Pharmacology, BVDU, Poona College of Pharmacy, Pune, 411038, Maharashtra, India.
- Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka, 575018, India.
- Faculty of Pharmacy, Moradabad Educational Trust, Moradabad, Uttar Pradesh, 244001, India.
- SOS School of Pharmacy, IFTM University, Moradabad, Uttar Pradesh, 244102, India.
- School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, 110017, India.
Zitieren
APA
Singh, H., Choudhary, H. B., Mandlik, D. S., Magre, M. S., Mohanto, S., Ahmed, M. G., Singh, B. K., Mishra, A. K., Kumar, A., Mishra, A., Venkatachalam, T., & Chopra, H. (2024). Molecular pathways and therapeutic strategies in dermatofibrosarcoma protuberans (DFSP). EXCLI Journal, 23, 727-762. https://doi.org/10.17179/excli2024-7164
Vancouver
Singh H, Choudhary HB, Mandlik DS, Magre MS, Mohanto S, Ahmed MG, et al. Molecular pathways and therapeutic strategies in dermatofibrosarcoma protuberans (DFSP). EXCLI Journal. 2024;23:727-762. doi:10.17179/excli2024-7164
BibTeX
@article{Singh2024,
author = {Singh, Harpreet and Choudhary, Heena Bholaram and Mandlik, Deepa Satish and Magre, Manoj Subhash and Mohanto, Sourav and Ahmed, Mohammed Gulzar and Singh, Bhuvnesh Kumar and Mishra, Arun Kumar and Kumar, Arvind and Mishra, Amrita and Venkatachalam, T and Chopra, Hitesh},
title = {Molecular pathways and therapeutic strategies in dermatofibrosarcoma protuberans (DFSP)},
journal = {EXCLI Journal},
year = {2024},
volume = {23},
pages = {727--762},
doi = {10.17179/excli2024-7164}
}
EUVIMED